摘要
目的：对NSCLC化疗药物基因组学方面的研究做一概述．并初步展望NSCLC化疗药物基因组学未来的发展。方法：回顾近年来NSCLC化疗药物基因组学方面的研究进展。结果和结论：肺癌是引起癌症患者死亡的主要原因之一．大约85％的肺癌患者为非小细胞肺癌，化疗是主要治疗手段。NSCLC化疗药物基因组学逐渐成为研究热点．并极有可能对肺癌的化疗产生重大改进。本文就NSCLC化疗药物基因组学方面的研究做一概述．并初步展望NSCLC化疗药物基因组学未来的发展。
Objective： To make a summary about progress on pharmacogenomics of non-small-cell lung cancer chemotherapy, and prospect the development of pharmacogenomics on NSCLC chemotherapy. Methods： To review the progress on pharmacogenomics of non-small-cell lung cancer chemotherapy in recent years. Results and Conclusions： Lung cancer is the major cause of cancer death. About 85% of patients with lung cancer are non-small cell lung cancer, and chemotherapy is the main treatment. NSCLC chemotherapy pharmacogenomics is becoming a hot research and is highly likely to have significant improvement on lung cancer chemotherapy. This article make a summary about progress on pharmacogenomics of non-small-cell lung cancer chemotherapy, and prospect the development ofpharmacogenomics on NSCLC chemotherapy.
出处
《药品评价》
CAS
2010年第22期33-38,共6页
Drug Evaluation
关键词
肺癌
药物基因组学
Lung cancer
Pharmacogenomics
